Flow cytometric evaluation and outcomes of pediatric acute leukemia patients

Ozkan, Ayse; BAYRAM, İBRAHİM; Tanyeli, Atila; CAVLAK, Burcu Genç; Küpeli, Serhan; Sezgin, Gülay

doi:10.17826/cumj.790247

Flow cytometric evaluation and outcomes of pediatric acute leukemia patients

Burcu Genç Cavlak, (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

Ayşe Özkan, (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

İbrahim Bayram, (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

Gülay Sezgin, (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

Serhan Küpeli, (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

Atila Tanyeli (Çukurova Üniversitesi, Tıp Fakültesi, Çocuk Onkolojisi Anabilim Dalı ve Çocuk Kemik İliği Nakli Ünitesi, Adana, Türkiye)

Cukurova Medical Journal

1 0

Yıl: 2021 Cilt: 46 Sayı: 1 Sayfa Aralığı: 149 - 159 Metin Dili: İngilizce DOI: 10.17826/cumj.790247 İndeks Tarihi: 30-06-2021

Flow cytometric evaluation and outcomes of pediatric acute leukemia patients

Öz:

Purpose: In this study, the outcomes and flow cytometryresults of our pediatric acute leukemia patients and theirrelationship with the prognosis and other clinicalconditions were investigated.Materials and Methods: A total of 93 patients, 69 acutelymphoblastic leukemia (ALL) and 24 acute myeloidleukemia (AML) diagnosed at our clinic between January2008 and November 2013, were included.Results: 5-year overall survival (OS) was 66% in ALLpatients and 80% in AML patients. When leukemiapatients were classified flow cytometrically according totheir cell surface antigens (CD); 5-year OS was 58% inCD2(+) patients and 77% in CD2(-) patients. Five-yearOS was 82% in patients with CD10(+) and 61% in patientswith CD10(-). ALL patients were divided into two groupsas ALL with positive T cell markers and ALL with positiveB cell markers in the foreground and evaluatedaccordingly, and the OS of ALL patients with positive Tcell markers in the foreground was lower than ALLpatients with positive B cell markers in the 5 year (59% and75%, respectively).Conclusion: In the flow cytometric evaluation of ourpatients with leukemia, patients with CD10(+) had a better5-year OS and patients with CD2(+) had a lower 5-yearOS. The results of patients with positive B cell markerswere better in ALL patients, and the results of patientswith positive lymphoid markers were better in AMLpatients.

Anahtar Kelime:

Çocukluk çağında akut lösemi tanısı alan hastaların sonuçları ve akım sitometri ile değerlendirilmesi

Öz:

hastalarının sonuçlarının ve akım sitometri sonuçlarının değerlendirilmesi, prognoz ve diğer klinik durumlar ile ilişkisinin araştırılması planlandı. Gereç ve Yöntem: Bu çalışmaya, Ocak 2008 ile Kasım 2013 arasında hastanemizde tanı alan 69 akut lenfoblastik lösemi (ALL) ve 24 akut miyeloid lösemi (AML) hastası olmak üzere toplam 93 hasta dahil edildi. Bulgular: Çalışmamızda, ALL hastalarında 5 yıllık genel sağkalım (OS) % 66, AML hastalarında ise % 80 saptandı. Lösemi hastaları, akım sitometrik olarak yüzey antijenlerine (CD) göre sınıflandırıldığında; CD2(+) hastalarda 5 yıllık OS % 58, CD2(-) hastalarda ise % 77 idi. CD10(+) hastalarda, 5 yıllık OS % 82, CD10(-) olan hastalarda ise % 61 idi. ALL hastaları, T ve B hücre belirteçleri pozitif ALL olarak iki gruba ayrılarak değerlendirildi; T hücre belirteçleri pozitif ALL hastalarının 5 yıllık OS’leri, B hücre belirteçleri pozitif ALL hastalarına göre daha düşük saptandı (sırasıyla % 59 ve % 75) (p=0.518) Sonuç: Lösemi hastalarımızın akım sitometri ile değerlendirilmesinde, CD10(+) olan hastaların 5 yıllık OS’lerinin daha iyi olduğu, CD2(+) olan hastalarda ise daha düşük olduğu saptandı. ALL hastalarında B hücre belirteçleri pozitif hastaların, AML hastalarında ise lenfoid belirteçleri pozitif hastaların sonuçları daha iyiydi

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. McKenney AH, Cleary ML, Arber DA. Pathology and Molecular Diagnosis of Leukemias and Lymphomas. In: Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;113-30.
2. Rabin KR, Gramatges MM, Margolin JF, Poplack DG. Acute Lymphoblastic Leukemia. In Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;463-97.
3. Arceci RJ, Meshinchi S. Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Pizzo PA and Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer. 2016;498-544.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. FrenchAmerican-British (FAB) co-operative group. Br J Haematol 1976, 33:451–8.
5. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukaemias. Leukaemia 1995;9:1783–6.
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. 2008; IARC Press, Lyon, France.
7. Leach M, Drummond M and Doig A. Acute Leukemia In: Leach M, Drummond M and Doig A Eds. Practical Flow Cytometry in Haematology Diagnosis, First ed. Wiley. 2013;43-93.
8. Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol. 2002;24:1–13.
9. Yan L, Ping N, Zhu M, Sun A, Xue Y, Ruan C et al. “Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO2008 classification’’. Haematologica. 2012;97:1708-12.
10. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with b-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-14
11. Bayram I, Erbey F, Kömür M, Tanyeli A. Total parenteral nutrition and decreased dose idarubicin based treatment of acute myeloid leukemia during childhood. Eur J Gen Med. 2010;7:282-87.
12. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–48.
13. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014.
14. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37:10- 19.
15. Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M et al. Increased post induction intensification improves outcome in children and adolescents with a markedly elevated White blood cell count (>200 × 109/L) with T cell Acute Lymphoblastic Leukemia but not B-cell disease: a report from the Children’s Oncology Group. Br J Haematol. 2015;168:533-46.
16. Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. British Medical Bulletin. 1996;52:82-703.
17. Ratei R, Schabath R, Karawajew L, Zimmermann M, Möricke A, Schrappe M et al. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. Klin Padiatr. 2013;225:34-9.
18. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:1663-9.
19. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and metaanalysis. Arch Dis Child. 2016;101:894-901
20. Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In Pizzo PA, Poplack DG, Eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott Williams- Wilkins. 2001:489-544.
21. Riehm H, Gadner H, Henze G. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970- 1976. Am J Pediatr Hematol Oncol. 1980;2:299.
22. Campbell M, Castillo L, Riccheri C, Janic D, Jazbec J, Kaiserova E et al. A randomized trial of the I- BFMSG for the management of childhood non- b acute lymphoblastic leukemia, ALL IC-BFM 2009- Trial Steering Committee. 2009;1-191.
23. Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematol Am Soc Hematol Educ Program. 2012;2012:129-36.
24. Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:957.
25. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60:4.
26. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer. 2007;109:157-63.
27. Liang DC, Chan TT, Lin KH, Lin DT, Lu MY, Chen SH et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia. 2006;20:136-41.
28. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005;23:9172-8.
29. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer Statistics,2008. CA Cancer J Clin. 2008;58:71-96.
30. Şaşmaz İ, Tanyeli A, Bayram İ, Antmen B, Yılmaz L, Küçükosmanoğlu O, Kılınç Y. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia. Turkish Journal of Pediatrics. 2004;46:32-7.
31. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch Pathol Lab Med. 2011;135:44-54.
32. Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62:47.
33. Ding B, Zhou L, Jiang X, Li X, Zhong Q, Wang Z et al. The Relationship between Clinical feature, complex immunophenotype, chromosome karyotype, and outcome of patients with acute myeloid leukemia in China. Dis Markers. 2015;2015:382186.

APA	CAVLAK B, Ozkan A, BAYRAM İ, Sezgin G, Küpeli S, Tanyeli A (2021). Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. , 149 - 159. 10.17826/cumj.790247
Chicago	CAVLAK Burcu Genç,Ozkan Ayse,BAYRAM İBRAHİM,Sezgin Gülay,Küpeli Serhan,Tanyeli Atila Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. (2021): 149 - 159. 10.17826/cumj.790247
MLA	CAVLAK Burcu Genç,Ozkan Ayse,BAYRAM İBRAHİM,Sezgin Gülay,Küpeli Serhan,Tanyeli Atila Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. , 2021, ss.149 - 159. 10.17826/cumj.790247
AMA	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. . 2021; 149 - 159. 10.17826/cumj.790247
Vancouver	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. . 2021; 149 - 159. 10.17826/cumj.790247
IEEE	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A "Flow cytometric evaluation and outcomes of pediatric acute leukemia patients." , ss.149 - 159, 2021. 10.17826/cumj.790247
ISNAD	CAVLAK, Burcu Genç vd. "Flow cytometric evaluation and outcomes of pediatric acute leukemia patients". (2021), 149-159. https://doi.org/10.17826/cumj.790247

APA	CAVLAK B, Ozkan A, BAYRAM İ, Sezgin G, Küpeli S, Tanyeli A (2021). Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. Cukurova Medical Journal, 46(1), 149 - 159. 10.17826/cumj.790247
Chicago	CAVLAK Burcu Genç,Ozkan Ayse,BAYRAM İBRAHİM,Sezgin Gülay,Küpeli Serhan,Tanyeli Atila Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. Cukurova Medical Journal 46, no.1 (2021): 149 - 159. 10.17826/cumj.790247
MLA	CAVLAK Burcu Genç,Ozkan Ayse,BAYRAM İBRAHİM,Sezgin Gülay,Küpeli Serhan,Tanyeli Atila Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. Cukurova Medical Journal, vol.46, no.1, 2021, ss.149 - 159. 10.17826/cumj.790247
AMA	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. Cukurova Medical Journal. 2021; 46(1): 149 - 159. 10.17826/cumj.790247
Vancouver	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A Flow cytometric evaluation and outcomes of pediatric acute leukemia patients. Cukurova Medical Journal. 2021; 46(1): 149 - 159. 10.17826/cumj.790247
IEEE	CAVLAK B,Ozkan A,BAYRAM İ,Sezgin G,Küpeli S,Tanyeli A "Flow cytometric evaluation and outcomes of pediatric acute leukemia patients." Cukurova Medical Journal, 46, ss.149 - 159, 2021. 10.17826/cumj.790247
ISNAD	CAVLAK, Burcu Genç vd. "Flow cytometric evaluation and outcomes of pediatric acute leukemia patients". Cukurova Medical Journal 46/1 (2021), 149-159. https://doi.org/10.17826/cumj.790247